Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$36.27 +3.0%	$32.03	$23.42 ▼ $62.58	$2.10B	0.73	651,361 shs	179,587 shs
INDV Indivior	$15.25 -1.9%	$12.87	$7.33 ▼ $15.88	$2.10B	0.65	1.24 million shs	590,860 shs
IRON Disc Medicine	$53.57 +0.4%	$49.49	$30.82 ▼ $68.73	$1.86B	0.76	337,988 shs	49,617 shs
KURA Kura Oncology	$5.89 +3.7%	$6.10	$5.41 ▼ $23.48	$509.90M	0.4	1.25 million shs	316,785 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-2.34%	+5.86%	+2.56%	+43.54%	-17.44%
INDV Indivior	-3.33%	+5.50%	+10.52%	+70.69%	+2.98%
IRON Disc Medicine	-2.49%	+0.79%	+6.72%	+55.72%	+14.50%
KURA Kura Oncology	-3.89%	-1.56%	-15.60%	+1.07%	-71.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	3.9666 of 5 stars	3.4	1.0	4.3	1.3	0.8	1.9
INDV Indivior	2.6328 of 5 stars	2.6	3.0	0.0	1.9	1.7	1.9
IRON Disc Medicine	3.158 of 5 stars	4.5	1.0	0.0	2.9	2.5	0.0
KURA Kura Oncology	4.5448 of 5 stars	4.4	3.0	4.7	1.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.71	Moderate Buy	$58.60	61.57% Upside
INDV Indivior	3.25	Buy	$17.00	11.48% Upside
IRON Disc Medicine	3.09	Buy	$96.70	80.51% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	315.96% Upside

Current Analyst Ratings Breakdown

Latest KURA, AGIO, INDV, and IRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/30/2025	INDV Indivior	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$37.04M	56.72	N/A	N/A	$27.02 per share	1.34
INDV Indivior	$1.17B	1.80	$1.80 per share	8.47	($2.52) per share	-6.05
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
KURA Kura Oncology	$53.88M	9.46	N/A	N/A	$5.32 per share	1.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	3.23	N/A	N/A	1,798.26%	-2.75%	-2.52%	7/30/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	8.92	N/A	-4.02%	-97.29%	15.74%	7/24/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)

Latest KURA, AGIO, INDV, and IRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	INDV Indivior	$0.25	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	18.50	17.93
INDV Indivior	N/A	0.88	0.72
IRON Disc Medicine	0.04	37.65	37.65
KURA Kura Oncology	0.02	8.07	8.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
INDV Indivior	60.33%
IRON Disc Medicine	83.70%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
INDV Indivior	N/A
IRON Disc Medicine	4.24%
KURA Kura Oncology	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	55.06 million	Optionable
INDV Indivior	1,051	137.88 million	N/A	Not Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable

KURA, AGIO, INDV, and IRON Headlines

Recent News About These Companies

Kura Oncology Grants Stock Options to New Employees Under 2023 Inducement Option Plan - Nasdaq

July 5 at 8:14 AM | nasdaq.com

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US - Investing.com

July 2, 2025 | investing.com

Kura Oncology's (KURA) Overweight Rating Reaffirmed at Cantor Fitzgerald

June 26, 2025 | marketbeat.com

Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Analysts

June 23, 2025 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Receives "Outperform" Rating from Wedbush

June 20, 2025 | marketbeat.com

Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook

June 15, 2025 | investing.com

Is the Options Market Predicting a Spike in Kura Oncology Stock?

June 12, 2025 | zacks.com

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

June 12, 2025 | globenewswire.com

Lightning Round: 'Wait and see situation' with Papa John's, says Jim Cramer

June 12, 2025 | msn.com

Brokers Issue Forecasts for Kura Oncology FY2026 Earnings

June 10, 2025 | marketbeat.com

Kura Oncology Grants Stock Options To New Hires Under Inducement Plan

June 7, 2025 | nasdaq.com

KURA Stock Rises More Than 15% This Past Week: Here's Why

June 6, 2025 | zacks.com

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

FDA Grants Priority Review to Ziftomenib Application in NPM1-Mutated Acute Myeloid Leukemia

June 5, 2025 | precisionmedicineonline.comP

FDA Grants Priority Review to NDA of Ziftomenib in NPM1-Mutant AML

June 4, 2025 | targetedonc.comT

ASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDA

June 3, 2025 | finance.yahoo.com

ASCO: Kura, Kyowa reveal 23% remission rate behind oral leukemia drug's phase 2 win

June 2, 2025 | fiercebiotech.comF

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

FDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin’s Ziftomenib

June 2, 2025 | insidermonkey.com

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

June 1, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/01/3091510/35186/en/kura-oncology-and-kyowa-kirin-announce-fda-acceptance-and-priority-review-of-new-drug-application-for-ziftomenib-in-adults-with-relapsed-or-refractory-npm1-mutant-aml.html$

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, AGIO, INDV, and IRON Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$36.27 +1.06 (+3.01%)

As of 12:57 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Indivior NASDAQ:INDV

$15.25 -0.30 (-1.93%)

As of 12:48 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Disc Medicine NASDAQ:IRON

$53.57 +0.19 (+0.36%)

As of 12:48 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Kura Oncology NASDAQ:KURA

$5.89 +0.21 (+3.70%)

As of 12:51 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time